1. Home
  2. GRI vs LICN Comparison

GRI vs LICN Comparison

Compare GRI & LICN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GRI
  • LICN
  • Stock Information
  • Founded
  • GRI 2018
  • LICN 2004
  • Country
  • GRI United States
  • LICN China
  • Employees
  • GRI N/A
  • LICN N/A
  • Industry
  • GRI Biotechnology: Pharmaceutical Preparations
  • LICN
  • Sector
  • GRI Health Care
  • LICN
  • Exchange
  • GRI Nasdaq
  • LICN Nasdaq
  • Market Cap
  • GRI 3.6M
  • LICN 3.1M
  • IPO Year
  • GRI N/A
  • LICN 2023
  • Fundamental
  • Price
  • GRI $1.43
  • LICN $4.58
  • Analyst Decision
  • GRI Strong Buy
  • LICN
  • Analyst Count
  • GRI 2
  • LICN 0
  • Target Price
  • GRI $22.00
  • LICN N/A
  • AVG Volume (30 Days)
  • GRI 84.2K
  • LICN 166.1K
  • Earning Date
  • GRI 08-14-2025
  • LICN 01-01-0001
  • Dividend Yield
  • GRI N/A
  • LICN N/A
  • EPS Growth
  • GRI N/A
  • LICN N/A
  • EPS
  • GRI N/A
  • LICN N/A
  • Revenue
  • GRI N/A
  • LICN $41,477,000.00
  • Revenue This Year
  • GRI N/A
  • LICN N/A
  • Revenue Next Year
  • GRI N/A
  • LICN N/A
  • P/E Ratio
  • GRI N/A
  • LICN N/A
  • Revenue Growth
  • GRI N/A
  • LICN 4.32
  • 52 Week Low
  • GRI $1.10
  • LICN $2.60
  • 52 Week High
  • GRI $30.43
  • LICN $462.00
  • Technical
  • Relative Strength Index (RSI)
  • GRI 48.16
  • LICN 52.10
  • Support Level
  • GRI $1.33
  • LICN $4.18
  • Resistance Level
  • GRI $1.45
  • LICN $4.92
  • Average True Range (ATR)
  • GRI 0.09
  • LICN 0.41
  • MACD
  • GRI 0.01
  • LICN 0.02
  • Stochastic Oscillator
  • GRI 53.61
  • LICN 41.24

About GRI GRI Bio Inc.

GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.

About LICN Lichen China Limited

Lichen International Ltd is a financial and taxation service provider in China. The company provides financial and taxation solution services; education support services; and software and maintenance services in the PRC under its Lichen brand. The financial and taxation solution services comprise financial and taxation related management consultation, internal control management consultation, annual or regular consultation, and internal training and general consultation. The education support services comprise the provision of marketing, operational and technical support and the sales of teaching and learning materials. The software and maintenance services comprise the sales of financial and taxation analysis software and sales of financial and taxation training software.

Share on Social Networks: